Our therapeutics stand apart from existing options, offering a unique precision and targeted approach. With superior efficacy, a favorable safety profile, and therefore improved patient compliance, our novel class of therapies sets a new standard for addressing this medical challenge.

Through groundbreaking research in neuroscience and chemistry, we have successfully developed and tested a new class of first-in-class small molecules. Our inventive approach targets untreatable epileptic patients and companion animals, providing effective and safe treatment options. With orally available, non-toxic, non-phototoxic, and non-neurotoxic drug candidates, 4NEURON positions itself to deliver cutting-edge solutions for patients and captures promising opportunities in the market.

The global epilepsy human therapeutics market already stands at an impressive $25 Bn with a promising CAGR of 5%. Additionally, the companion animal market demonstrates a faster-to-market CAGR. Historical data has shown that median efficient treatment options could generate over $50 Bn in 14 years. Our candidate stands out as it uniquely targets the root causes of epilepsy, providing for the first time a comprehensive and targeted treatment pathway for the large patient population.